ESCHeartFailure无左室

PrevalenceoftransthyretinamyloidosisinpatientswithheartfailureandnoleftventricularhypertrophyESCHeartFailureArticleEarlyRecent,May08,./ehf2.本文由“天纳”临床学术信息人工智能系统自动翻译点击文末“阅读原文”下载本文PDFAimsAsevidencedbyscintigraphyimaging,theprevalenceoftransthyretin(TTR)cardiacamyloidosisinheartfailurepatientswithpreservedejectionfraction(HFpEF)andleftventricularhypertrophy(LVH)rangesbetween13%and19%.Thenaturalevolutionofcardiacamyloidosisbeginswiththedepositionofamyloidmaterialinthemyocardium,withLVHensuingatlaterstages.Withcurrentimagingmodalities,itispossibletodetectTTRcardiacamyloidosisbeforethehypertrophicstage.TheaimofthisstudywastodeterminetheprevalenceofTTRcardiacamyloidosisinHFpEFpatientswithoutLVH.闪烁显像显示，射血分数（HFpEF）和左心室肥厚（LVH）维持的心力衰竭患者经甲状腺素（TTR）心肌淀粉样变的患病率在13%到19%之间。心脏淀粉样变的自然演变始于淀粉样物质在心肌的沉积，LVH随后发生在后期。利用目前的影像学检查方法，可以在肥厚期之前发现TTR心肌淀粉样变。本研究的目的是确定无LVH的HFpEF患者TTR心肌淀粉样变的患病率。MethodsandresultsThestudyprospectivelyenrolledpatientsadmittedforHFwithLVejectionfraction(LVEF)?≥?50%andLVwallthickness12?mm.TTRcardiacamyloidosiswasdiagnosedaccordingtoacceptedcriteria,whichincludepositivecardiac99‐Tc‐DPDscintigraphyintheabsenceofmonoclonalproteinexpansioninblood.Transthyretingenesequencingwasperformedinpositivepatients.FromJulytoJanuary,patientswithHFpEFandLVthickness12?mmwereidentified.Afterexclusions,58patients

转载请注明：http://www.tengdameikuang.com/yfzl/10184.html